| abstract |
The present invention relates to the use of compounds that bind to vascular endothelial growth factor receptor and modulate angiogenic responses. Compounds that mimic the VEGF amino acid region 17-25 involved in receptor recognition and thereby inhibit or stimulate the angiogenic process are diseases characterized by excessive or insufficient VEGF-dependent angiogenesis, such as , Chronic ischemia, cancer, proliferative retinopathy and rheumatoid arthritis, in the treatment of conditions or conditions that benefit from the formation or regeneration of new blood vessels, and in the diagnosis of lesions exhibiting VEGF receptor overexpression, or VEGF reception It can be used as a biochemical tool to analyze cellular pathways that depend on body activation. |